Skip to main content
. 2014 Oct 22;9(10):e109235. doi: 10.1371/journal.pone.0109235

Table 2. Associations between SNPs of MTHFR, MTR, MTRR, DNMT1, and ALDH2 genes and cancers of the esophagus, stomach, and liver.

Esophageal Cancer Stomach Cancer Liver Cancer
Ca/Co SBOR1 (95% posterior limit) One-sidedP * SBOR2 (95% posterior limit) One-sidedP * Ca/Co SBOR1 (95% posterior limit) One-sided P * SBOR2 (95% posterior limit) One- sided P * Ca/Co SBOR1 (95% posterior limit) One- sided P * SBOR2 (95% posterior limit) One- sided P *
MTHFR
rs1801133
CC 65/135 1.00 1.00 50/135 1.00 1.00 50/135 1.00 1.00
CT 105/199 1.15 (0.79, 1.65) 0.24 1.19 (0.80, 1.77) 0.20 106/199 1.38 (0.94, 2.02) 0.050 1.53 (1.00, 2.33) 0.024 114/199 1.46 (1.00, 2.13) 0.026 1.57 (1.02, 2.42) 0.021
TT 32/57 1.13 (0.69, 1.86) 0.32 1.35 (0.78, 2.32) 0.14 38/57 1.66 (1.02, 2.71) 0.021 2.26 (1.30, 3.91) 0.002 30/57 1.31(0.78, 2.19) 0.15 1.17 (0.64, 2.12) 0.31
P trend 0.50 0.21 0.021 0.001 0.12 0.24
Dominant 1.15 (0.81, 1.64) 0.22 1.25 (0.85, 1.84) 0.13 1.49 (1.03, 2.16) 0.018 1.79 (1.18, 2.71) 0.003 1.46 (1.00, 2.12) 0.024 1.51 (0.98, 2.32) 0.029
Recessive 1.05 (0.67, 1.66) 0.41 1.23 (0.74, 2.03) 0.21 1.38 (0.90, 2.14) 0.072 1.78 (1.09, 2.91) 0.011 1.05 (0.66, 1.67) 0.41 0.91 (0.53, 1.56) 0.37
MTR
rs1805087
A/A 161/310 1.00 1.00 142/310 1.00 1.00 149/310 1.00 1.00
A/G 35/76 0.90 (0.58, 1.37) 0.31 0.79 (0.50, 1.27) 0.17 46/76 1.31 (0.87, 1.96) 0.096 1.16 (0.74, 1.83) 0.26 40/76 1.03 (0.68, 1.56) 0.45 0.92 (0.57, 1.47) 0.36
G/G 4/0 1/0 1/0
Dominant 1.01 (0.66, 1.52) 0.49 0.90 (0.57, 1.42) 0.32 1.34 (0.90, 2.00) 0.078 1.19 (0.76, 1.87) 0.22 1.05 (0.69, 1.59) 0.41 0.93 (0.58, 1.49) 0.38
MTRR
rs1532268
C/C 145/283 1.00 1.00 144/283 1.00 1.00 149/283 1.00 1.00
C/T 47/94 0.99 (0.67, 1.46) 0.47 1.16 (0.76, 1.78) 0.25 44/94 0.96 (0.65, 1.43) 0.42 0.98 (0.63, 1.53) 0.47 39/94 0.77 (0.51, 1.15) 0.10 0.83 (0.52, 1.32) 0.21
T/T 11/11 1.80 (0.86, 3.80) 0.060 1.96 (0.89, 4.31) 0.047 5/11 1.08 (0.45, 2.56) 0.43 1.05 (0.43, 2.57) 0.46 4/11 0.75 (0.31, 1.82) 0.27 1.09 (0.42, 2.82) 0.43
P trend 0.27 0.070 0.98 0.97 0.14 0.61
Dominant 1.11 (0.77, 1.61) 0.29 1.32 (0.88, 1.98) 0.089 0.98 (0.67, 1.44) 0.45 1.00 (0.65, 1.52) 0.49 0.75 (0.50, 1.11) 0.075 0.85 (0.54, 1.34) 0.25
Recessive 1.81 (0.86, 3.80) 0.059 1.91 (0.87, 4.19) 0.052 1.09 (0.46, 2.58) 0.43 1.06 (0.43, 2.57) 0.45 0.78 (0.33, 1.89) 0.30 1.12 (0.43, 2.90) 0.41
rs1801394
A/A 117/204 1.00 1.00 119/204 1.00 1.00 114/204 1.00 1.00
A/G 74/149 0.88 (0.62, 1.25) 0.24 0.92 (0.63, 1.35) 0.34 63/149 0.75 (0.53, 1.08) 0.063 0.74 (0.49, 1.11) 0.070 64/149 0.78 (0.54, 1.12) 0.092 0.74 (0.49, 1.12) 0.078
G/G 10/25 0.81 (0.42, 1.59) 0.27 0.95 (0.47, 1.93) 0.44 9/25 0.76 (0.38, 1.50) 0.21 0.77 (0.37, 1.60) 0.24 13/25 0.93 (0.49, 1.75) 0.41 1.39 (0.70, 2.78) 0.17
P trend 0.36 0.70 0.10 0.13 0.30 0.87
Dominant 0.86 (0.61, 1.21) 0.20 0.92 (0.64, 1.34) 0.33 0.74 (0.52, 1.05) 0.046 0.73 (0.49, 1.07) 0.055 0.80 (0.56, 1.13) 0.10 0.83 (0.56, 1.24) 0.19
Recessive 0.85 (0.44, 1.64) 0.31 0.97 (0.48, 1.96) 0.47 0.82 (0.41, 1.62) 0.29 0.84 (0.41, 1.74) 0.32 1.00 (0.54, 1.88) 0.50 1.53 (0.78, 3.03) 0.11
DNMT1
rs2228612
A/A 52/100 1.00 1.00 43/100 1.00 1.00 48/100 1.00 1.00
A/G 56/200 0.58 (0.38, 0.88) 0.006 0.52 (0.33, 0.82) 0.003 72/200 0.84 (0.55, 1.28) 0.21 0.82 (0.51, 1.31) 0.20 74/200 0.79 (0.52, 1.19) 0.13 0.79 (0.49, 1.28) 0.17
G/G 29/57 1.03 (0.61, 1.73) 0.46 0.96 (0.55, 1.68) 0.44 28/57 1.11 (0.65, 1.89) 0.36 1.12 (0.62, 2.04) 0.35 36/57 1.33 (0.80, 2.22) 0.13 1.35 (0.76, 2.42) 0.15
P trend 0.57 0.37 0.88 0.88 0.42 0.42
Dominant 0.67 (0.45, 1.00) 0.026 0.60 (0.39, 0.94) 0.012 0.90 (0.59, 1.36) 0.31 0.89 (0.56, 1.41) 0.31 0.92 (0.62, 1.37) 0.34 0.93 (0.58, 1.50) 0.39
Recessive 1.38 (0.86, 2.21) 0.092 1.35 (0.81, 2.25) 0.13 1.22 (0.76, 1.97) 0.20 1.26 (0.74, 2.15) 0.20 1.53 (0.97, 2.40) 0.033 1.54 (0.92, 2.59) 0.051
ALDH2
rs671
G/G 118/213 1.00 1.00 108/213 1.00 1.00 109/213 1.00 1.00
A/G 60/160 0.70 (0.49, 1.01) 0.029 0.76 (0.51, 1.13) 0.088 76/160 0.97 (0.68, 1.38) 0.44 1.06 (0.71, 1.57) 0.39 74/160 0.91 (0.64, 1.30) 0.31 1.05 (0.70, 1.58) 0.41
A/A 25/20 1.97 (1.11, 3.49) 0.010 1.61 (0.86, 3.00) 0.066 12/20 1.13 (0.58, 2.21) 0.36 0.99 (0.48, 2.03) 0.49 10/20 1.03 (0.51, 2.06) 0.47 0.96 (0.45, 2.06) 0.46
P trend 0.49 0.67 0.88 0.88 0.77 0.94
Dominant 0.88 (0.63, 1.24) 0.24 0.90 (0.62, 1.31) 0.29 1.00 (0.71, 1.40) 0.49 1.05 (0.71, 1.54) 0.41 0.93 (0.66, 1.31) 0.33 1.04 (0.70, 1.54) 0.43
Recessive 2.20 (1.25, 3.86) 0.003 1.76 (0.96, 3.24) 0.035 1.14 (0.59, 2.21) 0.35 0.97 (0.48, 1.97) 0.47 1.06 (0.53, 2.10) 0.44 0.95 (0.45, 2.01) 0.44
rs2238151
C/C 173/293 1.00 1.00 151/293 1.00 1.00 166/293 1.00 1.00
C/T 11/34 0.66 (0.35, 1.22) 0.093 0.66 (0.34, 1.29) 0.11 18/34 1.08 (0.61, 1.89) 0.40 1.21 (0.65, 2.23) 0.28 7/34 0.44 (0.22, 0.87) 0.009 0.51 (0.23, 1.11) 0.045
T/T 0/1 0/1 1/1 1.15 (0.33, 4.03) 0.41 1.43 (0.39, 5.33) 0.30
P trend 0.045 0.29
Dominant 0.64 (0.35, 1.19) 0.079 0.65 (0.33, 1.28) 0.11 1.05 (0.60, 1.83) 0.43 1.20 (0.65, 2.21) 0.29 0.47 (0.24, 0.92) 0.013 0.58 (0.27, 1.25) 0.082
Recessive 1.16 (0.33, 4.07) 0.41 1.44 (0.39, 5.37) 0.29
rs886205
G/G 173/315 1.00 1.00 150/315 1.00 1.00 149/315 1.00 1.00
A/G 29/69 0.81 (0.51, 1.26) 0.17 0.78 (0.48, 1.28) 0.17 41/69 1.23 (0.81, 1.87) 0.17 1.47 (0.92, 2.34) 0.054 40/69 1.19 (0.78, 1.81) 0.21 1.38 (0.85, 2.24) 0.096
A/A 2/4 1.07 (0.36, 3.18) 0.45 1.00 (0.33, 3.08) 0.50 2/4 1.10 (0.37, 3.30) 0.43 1.18 (0.39, 3.65) 0.38 2/4 1.00 (0.34, 2.96) 0.50 1.27 (0.40, 4.10) 0.34
P trend 0.45 0.39 0.32 0.098 0.47 0.14
Dominant 0.82 (0.53, 1.28) 0.19 0.79 (0.49, 1.29) 0.17 1.23 (0.82, 1.86) 0.16 1.48 (0.93, 2.34) 0.047 1.18 (0.78, 1.79) 0.22 1.41 (0.88, 2.28) 0.076
Recessive 1.08 (0.36, 3.23) 0.44 1.02 (0.33, 3.13) 0.49 1.08 (0.36, 3.24) 0.44 1.16 (0.38, 3.55) 0.40 0.98 (0.33, 2.92) 0.49 1.25 (0.39, 4.03) 0.35
1

: Semi-Bayes odds ratio (SBOR) adjusted for age (5-year categories and deviation from stratum mean) and sex.

2

: SBOR further adjusted for residency (city, rural), alcohol drinking frequency, smoking pack-years, BMI, education, H. pylori infection (in stomach cancer analyses), HBsAg (in liver cancer analyses), and plasma AFB1 levels (in liver cancer analyses), based on the assumption that genotype did not affect any of these variables.

*: One-sided semi-Bayes P-values; the posterior probability that the point estimate is on the wrong side of the null [26], [27].

: P-value from Chi-Square test for trend.